VistaGen to Participate in Upcoming June Investor Conferences
May 27 2022 - 8:30AM
Business Wire
VistaGen will present at upcoming William Blair
42nd Annual Growth Stock Conference and Jefferies Global Healthcare
Conference
VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late
clinical-stage, central nervous system (CNS)-focused
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression, and
other CNS disorders, today announced that Shawn Singh, Chief
Executive Officer, will participate in the following upcoming
investor conferences in June. Management will be available for
one-on-one meetings during these conferences.
William Blair 42nd Annual Growth Stock Conference Format:
Fireside Chat Date and Time: Tuesday, June 7th at 2:00pm Central
Time Location: Chicago, IL
Jefferies Global Healthcare Conference Format: Company
Presentation Date and Time: Thursday, June 9th at 10:00am Eastern
Time Location: New York, NY
The live and archived webcasts of VistaGen’s fireside chat and
presentation will be accessible through the News/Events page of the
Investors section of the Company’s website at www.VistaGen.com.
About VistaGen VistaGen (Nasdaq: VTGN) is a late
clinical-stage, CNS-focused biopharmaceutical company striving to
transform the treatment landscape for individuals living with
anxiety, depression and other CNS disorders. The Company is
advancing first-in-class therapeutics with the potential to be
faster-acting, and with fewer side effects and safety concerns,
than those that are currently available. VistaGen’s clinical-stage
candidates are targeting multiple forms of anxiety and depression.
They belong to a new class of drugs known as pherines, which are
odorless, neuroactive steroids that bind to distinct receptors on
chemosensory neurons in the nasal passages and can impact the
olfactory to limbic amygdala circuit without systemic uptake or
direct activity on CNS neurons in the brain. VistaGen’s lead
candidate, PH94B, is a nasally administered spray currently in
multiple Phase 3 trials in the U.S., with results anticipated in
2022. Should ongoing Phase 3 studies be successful, PH94B has the
potential to be the first FDA-approved, fast-acting, acute
treatment of anxiety for adults with social anxiety disorder. With
an experienced leadership team and a steady flow of near- and
long-term potential milestones, VistaGen is passionate about
transforming mental health care and redefining what is possible in
the treatment of anxiety and depression. Connect at
www.VistaGen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220527005062/en/
Investors Mark Flather Vice President, Investor
Relations, VistaGen Therapeutics Phone: (650) 577-3617 Email:
mflather@vistagen.com Media Nate Hitchings SKDK Email:
nhitchings@skdknick.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024